Antibody response to melanoma helper-peptide vaccine correlates with survival

por Olson, Walter C, Reed, Caroline M, Slingluff, Craig L
Publicado 2013

Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine

por Tran, Christine A, Lynch, Kevin T, Meneveau, Max O, Katyal, Priya, Olson, Walter C, Slingluff,, Craig L
Publicado 2023

Vaccine-draining lymph nodes of cancer patients for generating anti-cancer antibodies

por Shukla, Girja S., Olson, Walter C., Pero, Stephanie C., Sun, Yu-jing, Carman, Chelsea L., Slingluff, Craig L., Krag, David N.
Publicado 2017

Immunologic hierarchy and promiscuity of melanoma helper peptides

por Hu, Yinin, Petroni, Gina R, Olson, Walter C, Czarkowski, Andrea, Smolkin, Mark, Grosh, William W, Rehm, Patrice K, Murphy, Cheryl F, Coleman, Elizabeth J
Publicado 2013

Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield,...

por Olson, Walter C, Smolkin, Mark E, Farris, Erin M, Fink, Robyn J, Czarkowski, Andrea R, Fink, Jonathan H, Chianese-Bullock, Kimberly A, Slingluff, Craig L
Publicado 2011

A multi-epitope melanoma helper peptide vaccine durably increases Th1 cytokine production by responding lymphocytes

por Dillon, Patrick M, Olson, Walter C, Czarkowski, Andrea, Petroni, Gina R, Smolkin, Mark, Grosh, William W, Chianese-Bullock, Kimberly A, Deacon, Donna H, Slingluff, Craig L
Publicado 2013

A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes

por Dillon, Patrick M, Olson, Walter C, Czarkowski, Andrea, Petroni, Gina R, Smolkin, Mark, Grosh, William W, Chianese-Bullock, Kimberly A, Deacon, Donna H, Slingluff, Craig L
Publicado 2014

A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes

por Slingluff, Craig L, Petroni, Gina R, Olson, Walter C, Chianese-bullock, Kimberly A, Smith, Kelly T, Smolkin, Mark E, Galeassi, Nadedja, Grosh, William, Weiss, Geoffrey, Scott, Kristy, Hornillo, Ana
Publicado 2014

Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer

por Knapp, Kiley A., Pires, Eusebio S., Adair, Sara J., Mandal, Arabinda, Mills, Anne M., Olson, Walter C., Slingluff, Craig L., Parsons, J. Thomas, Bauer, Todd W., Bullock, Timothy N., Herr, John C.
Publicado 2018

Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist

por Meneveau, Max O, Petroni, Gina R, Salerno, Elise P, Lynch, Kevin T, Smolkin, Mark, Woodson, Elizabeth, Chianese-Bullock, Kimberly A, Olson, Walter C, Deacon, Donna, Patterson, James W, Grosh, William W, Slingluff, Craig L
Publicado 2021

Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)

por Vavolizza, Rick D, Petroni, Gina R, Mauldin, Ileana S, Chianese-Bullock, Kimberly A, Olson, Walter C, Smith, Kelly T, Dengel, Lynn T, Haden, Kathleen, Grosh, William W, Kaur, Varinder, Varhegyi, Nikole, Gaughan, Elizabeth M, Slingluff, Craig L
Publicado 2022

A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer

por Dillon, Patrick M., Petroni, Gina R., Smolkin, Mark E., Brenin, David R., Chianese-Bullock, Kimberly A., Smith, Kelly T., Olson, Walter C., Fanous, Ibrahim S., Nail, Carmel J., Brenin, Christiana M., Hall, Emily H., Slingluff, Craig L.
Publicado 2017

Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma

por Patel, Sapna P, Petroni, Gina R, Roszik, Jason, Olson, Walter C, Wages, Nolan A, Chianese-Bullock, Kimberly A, Smolkin, Mark, Varhegyi, Nikole, Gaughan, Elizabeth, Smith, Kelly T, Haden, Kathleen, Hall, Emily H, Gnjatic, Sacha, Hwu, Patrick, Slingluff, Craig L
Publicado 2021

Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine

por Mauldin, Ileana S, Wages, Nolan A, Stowman, Anne M, Wang, Ena, Smolkin, Mark E, Olson, Walter C, Deacon, Donna H, Smith, Kelly T, Galeassi, Nadejda, Teague, Jessica E, Clark, Rachael A, Marincola, Francesco M, Petroni, Gina R, Mullins, David W, Slingluff, Craig L
Publicado 2015

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma

por Slingluff, Craig L., Zarour, Hassane M., Tawbi, Hussein Abdul-Hassan, Kirkwood, John M., Postow, Michael A., Friedlander, Philip, Devoe, Craig E., Gaughan, Elizabeth M., Mauldin, Ileana S., Olson, Walter C., Smith, Kelly T., Macri, Mary J., Ricciardi, Toni, Ryan, Aileen, Venhaus, Ralph, Wolchok, Jedd D.
Publicado 2021

Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)

por Slingluff, Jr., Craig L, Petroni, Gina R, Chianese-Bullock, Kimberly A, Wages, Nolan A, Olson, Walter C, Smith, Kelly T, Haden, Kathleen, Dengel, Lynn T, Dickinson, Anna, Reed, Caroline, Gaughan, Elizabeth M, Grosh, William W, Kaur, Varinder, Varhegyi, Nikole, Smolkin, Mark, Galeassi, Nadejda V, Deacon, Donna, Hall, Emily H
Publicado 2021